CPK 850

Drug Profile

CPK 850

Alternative Names: CPK850; CPK850 Gene Therapy; scAAV8-pRLBP1(short)-hRLBP1 vector; scAAV8-RLBP1

Latest Information Update: 28 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis Pharmaceuticals
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Retinitis pigmentosa

Most Recent Events

  • 22 Dec 2017 Pharmacodynamics data from a preclinical trials in Retinitis pigmentosa released by Novartis
  • 17 Dec 2017 Novartis Pharmaceuticals plans a first-in-human phase I trial for Retinitis pigmentosa (Intraocular) in April 2018 (NCT03374657)
  • 17 Dec 2017 Preclinical trials in Retinitis pigmentosa in USA (Intraocular) before December 2017 (NCT03374657)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top